Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study
Hepatology International - 2022
Tóm tắt
Whether the efficacies of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in treating liver-related outcomes of decompensated chronic hepatitis B (CHB) patients are comparable remained inconclusive. An 8-year cohort study of 736 decompensated CHB patients was conducted, and 65 TDF-treated patients were sex, age and model for end-stage liver disease (MELD) scores-1:4 matched with 260 ETV-treated patients through propensity score-matching method. Of 736 patients, 574 (78%) were male, with a mean age of 54.3 years, 438 (59.5%) had cirrhosis, 147 (20%) were positive for HBeAg, and 84 (11.6%) and 652 (88.4%) were treated with TDF and ETV, respectively. The 652 ETV-treated patients were older, had higher baseline MELD score and rates of encephalopathy, but lower ALT levels than the 84 TDF-treated patients. No significant differences were observed in the cumulative incidences of liver-related mortality or liver transplantation (1-month, 18.45 vs. 14.01%, p = 0.368; 8-year, 39.74 vs. 34.24%, p = 0.298), and hepatocellular carcinoma development (5-year, 7.21 vs.13.17%, p = 0.994; 8-year, 11.60 vs.13.17%, p = 0.857) between the matched 260 ETV- and 65 TDF-treated patients, regardless of time points. Baseline MELD score (subdistribution hazard ratio (sHR): 1.063; 95% confidence interval (CI) of sHR: 1.016–1.112) and hepatic encephalopathy (sHR: 5.127; 95% CI sHR: 3.032–8.669) were independently associated with liver-related mortality or liver transplantation in the matched patients. ETV and TDF had comparable efficacy in the short- and long-term liver-related outcomes of decompensated CHB patients, and baseline liver reserve was associated with the outcomes.
Từ khóa
Tài liệu tham khảo
Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442–450
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599
Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561
Chang ML, Cheng JS, Chien RN, et al. Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2020;18:2064-2072.e2
Lin B, Pan CQ, Xie D, et al. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013;7:460–467
Wan YM, Li YH, Xu ZY, et al. Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C. J Clin Gastroenterol. 2019;53:e171–e177
Wu J, Yin F, Zhou X. Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis. Acta Pharm. 2018;68:19–30
Hung CH, Hu TH, Lu SN, et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother. 2015;59:3168–3173
Park JG, Lee YR, Park SY, et al. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. Dig Liver Dis. 2018;50:163–167
Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631–641
Lee WC, Lee CS, Wang YC, et al. Validation of the model for end-stage liver disease score criteria in urgent liver transplantation for acute flare up of hepatitis B. Medicine (Baltimore). 2016;95: e3609
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1998;16:1141–1154
Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a competing risk. J AM STAT ASSOC. 1999;94:496–509
Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719–727
Furihata T, Morio H, Zhu M, et al. Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017;32:116–119
Castillo-Mancilla JR, Meditz A, Wilson C, et al. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J Acquir Immune Defic Syndr. 2015;68:495–501
Chang ML, Liaw YF. Hepatitis B flare in hepatitis B e antigen-negative patients: a complicated cascade of innate and adaptive immune responses. Int J Mol Sci. 2022;23:1552
Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218–1229
Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144–151
Gao L, Trinh HN, Li J, et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther. 2014;39:629–637
Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS ONE. 2014;9: e98865
Batirel A, Guclu E, Arslan F, et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014;28:153–159
Ozaras R, Mete B, Ceylan B, et al. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. Eur J Gastroenterol Hepatol. 2014;26:774–780
Lei JH, Peng F, Chen Z, et al. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis. 2019;19:363
Gao F, Sun L, Ye X, et al. Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure. Eur J Gastroenterol Hepatol. 2017;29:669–678
Chen WT, Lee MS, Chang CL, et al. Retinol-binding protein-4 expression marks the short-term mortality of critically ill patients with underlying liver disease: Lipid, but not glucose, matters. Sci Rep. 2017;7:2881
Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–327
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352
Su TH, Hu TH, Chen CY, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764
Jeng WJ, Liaw YF. Finite antiviral therapy in chronic hepatitis B patients with cirrhosis. Semin Liver Dis. 2021;41:349–357
Dave S, Park S, Murad MH, et al. Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatology. 2021;73:68–78
Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic Hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039–1052
Jung WJ, Jang JY, Park WY, et al. Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore). 2018;97: e9756
Saeedi R, Mojebi-Mogharar A, Sandhu SK, et al. Lamivudine, entecavir, or tenofovir treatment of hepatitis B infection: effects on calcium, phosphate, FGF23 and indicators of bone metabolism. Ann Hepatol. 2017;16:207–14
Saeedi R, Mojebi-Mogharar A, Sandhu SK, et al. Lamivudine, entecavir, or tenofovir treatment of hepatitis B infection: effects on calcium, phosphate, FGF23 and indicators of bone metabolism. Ann Hepatol. 2017;16:207–214